Table 5 Stratification analyses by clinical characteristics for the association between CYP19A1 polymorphisms and the risk of lung cancer

rs28757157

Genotype

C/C

313 (67.2%)

108 (60%)

1

0.240

70 (56.5%)

1

0.099

T/C

144 (30.9%)

69 (38.3%)

1.37 (0.95–1.98)

50 (40.3%)

1.60 (1.04–2.46)

T/T

9 (1.9%)

3 (1.7%)

0.97 (0.25–3.71)

4 (3.2%)

1.56 (0.45–5.40)

Dominant

C/C

313 (67.2%)

108 (60%)

1

0.110

70 (56.5%)

1

0.032

T/C-T/T

153 (32.8%)

72 (40%)

1.35 (0.94–1.94)

54 (43.5%)

1.59 (1.04–2.43)

Recessive

C/C-T/C

457 (98.1%)

177 (98.3%)

1

0.820

120 (96.8%)

1

0.690

T/T

9 (1.9%)

3 (1.7%)

0.86 (0.23–3.27)

4 (3.2%)

1.29 (0.38–4.41)

Log-additive

–-

–-

–-

1.27 (0.91–1.77)

0.160

–-

1.48 (1.02–2.15)

0.042

rs3751592

Genotype

T/T

368 (78.8%)

152 (81.3%)

1

0.011

99 (75%)

1

0.260

C/T

93 (19.9%)

26 (13.9%)

0.67 (0.41–1.08)

29 (22%)

1.16 (0.71–1.91)

C/C

6 (1.3%)

9 (4.8%)

3.57 (1.22–10.42)

4 (3%)

3.08 (0.79–12.04)

Dominant

T/T

368 (78.8%)

152 (81.3%)

1

0.440

99 (75%)

1

0.330

C/T-C/C

99 (21.2%)

35 (18.7%)

0.84 (0.54–1.31)

33 (25%)

1.27 (0.79–2.03)

Recessive

T/T-C/T

461 (98.7%)

178 (95.2%)

1

0.013

128 (97%)

1

0.130

C/C

6 (1.3%)

9 (4.8%)

3.84 (1.32–11.17)

4 (3%)

2.99 (0.77–11.64)

Log-additive

–-

–-

–-

1.04 (0.72–1.49)

0.850

–-

1.33 (0.87–2.01)

0.190